Skip to main content
. 2023 Oct 30;16:17562864231207755. doi: 10.1177/17562864231207755

Figure 2.

Figure 2.

(a–e) Responder rates. (a) Overall, (b) age subgroups, (c) CBD dose subgroups, (d) concomitant ASMs subgroups, (e) epilepsy syndromes subgroups, and (f) pooled outcomes at 12 weeks across study designs.

ASM, antiseizure medication; CBD, cannabidiol.